Joe Rogan Experience #2469 - Brigham Buhler
In a Nutshell
Brigham Buhler details ongoing efforts with the new HHS/FDA leadership under Kennedy to reclassify peptides, debunk testosterone-prostate cancer myths, and create regulatory pathways for peptides, stem cells (especially Muse cells), and compounding pharmacies, countering Big Pharma lobbying that protects patents and stifles proactive, cash-pay healthspan medicine. He critiques the chronic disease-focused U.S. healthcare system—highest spending, worst outcomes—and advocates state-level actions (Texas, Florida) plus a parallel "life raft" model using AI, genetics, DEXA scans, and therapies like plasma feresis for personalized prevention over symptom treatment. Key wins include HHS removing hormone black box warnings; Muse cells emerge as a safe, pluripotent breakthrough for regeneration, outperforming traditional MSCs in homing, safety, and results for injuries, neurodegeneration, and longevity.
These notes were generated by AI and may contain inaccuracies.
Joe Rogan mentions having allergies, sounding stuffed up, initially thinking he might be sick but feeling great physically after working out. They discuss environmental factors in Austin like cedar pollen, which affected Rogan severely when he first moved from Houston (pine trees there). Body adapts over time. Brigham recommends colostrum daily for allergies; consistency makes a big difference.
Brigham updates on administration working to reclassify peptides, unveiled on Rogan's podcast with Secretary Kennedy a few weeks ago. Labor of love for 2.5-3 years. Most optimistic ever with reason. Prior FDA administration classified peptides as dangerous like a Trojan horse before Kennedy's team took over. Submitted 17 FOIA requests to FDA for clarity on safety and decisions; no responses despite legal requirement. Now have seat at table with accessibility.
Kennedy uses peptides, knows benefits, is fit and educated. Millions use them for improved health and vitality; both Rogan and Brigham are users.
Brigham was typical American patient: on cusp of diabetes, obese former fat kid in late 30s, trusted system with annual blood work but declined due to systemic issues. Peptides nuanced for FDA legacy employees. Thanks to new administration, meetings with Stephanie Spear (Kennedy's right-hand), Marty Makary (FDA head, book Blind Spot), testified together at Senate. Makary open-minded, admits not intimate with peptides as surgeon but willing to research.
Sign in to read the full notes
Get access to AI-generated notes, topic timestamps, and more.